Business Wire

Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion ...

WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the DynamX ...
Yahoo Finance

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...
Destination CRM

Lithium Technologies Acquires Social Dynamx

Lithium Technologies, a developer of customer community platforms, has acquired enterprise social customer care solution Social Dynamx. The company also announced the general release of the product ...
Business Wire

Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized ...
VentureBeat

Update: Lithium Technologies issues $5.6M in shares to buy Social Dynamx

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Lithium Technologies has issued $5.6 million in shares to power its ...
Yahoo Finance

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

MILPITAS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced new landmark clinical results for its ...
EurekAlert!

DynamX Bioadaptor, a novel 'uncaging' platform for coronary artery revascularisation

Drug Eluting Stents (DES) are the mainstay of coronary artery disease treatment. Although DES design iterations have reduced MACE in the first year after PCI, beyond 1-year, a persistent 2-3% ...
CRM Buyer

Social Dynamx Turns CSRs Into Rock Stars

Social Dynamx has just launched a new enterprise-class social customer care (social CRM) platform that will allow customer support and community management teams to identify, prioritize and handle ...
EDN

Social Dynamx Launches to Redefine Social Customer Care

Consumers now broadcast their opinions instantly to thousands, or even millions, of people from wherever they are. Social Dynamx quickly identifies relevant conversations and intelligently routes them ...
News Medical

FDA Grants clearance to MXO's dynaMX Compression Staple featuring Malleable Nitinol Technology

MX Orthopedics, Corp. (MXO), a leader in superelastic technologies for orthopedic implants, announces the recent FDA clearance (K143622) of its patent-pending dynaMX™ Compression Staple featuring ...
manilatimes

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

DynamX® bioadaptor is the first interventional technology to demonstrate significant benefit with a reduction in long term adverse events in two consecutive randomized controlled trials MILPITAS, ...